Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advances in Prostate Cancer: Androgen Deprivation Therapy Across the Disease Continuum
  • CME

Credits Available
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: October 6, 2021 Expiration: October 5, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Astellas
Bayer HealthCare Pharmaceuticals Inc.
Myovant Sciences Ltd.
Pfizer, Inc.
Daniel W. Lin, MD
Alicia K. Morgans, MD, MPH
David F. Penson, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients who are likely to benefit from newly available therapeutic options for nonmetastatic prostate cancer
  • Plan optimal, individualized therapeutic strategies for nonmetastatic or metastatic castration-sensitive prostate cancer
  • Apply guidelines and expert recommendations for the sequencing of available and emerging therapies (alone and in combination) for patients with prostate cancer
  • Assess and manage the risk for cardiotoxicity or bone loss before and/or during prostate cancer treatment
  • Counsel patients about available ADTs, taking into consideration patient preferences and comorbidities with regard to differences in administration and safety profiles
  • Refer appropriate patients with prostate cancer to ongoing clinical trials assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Daniel W. Lin, MD

Professor and Chief of Urologic Oncology
Department of Urology
University of Washington
Seattle, Washington

Daniel W. Lin, MD, has disclosed that he has received funds for research support from Decipher, Genomic Health, MagForce, and MDxHealth; consulting fees from Astellas, Clovis Oncology, and Janssen; and other financial or material support from AstraZeneca.
Alicia K. Morgans, MD, MPH

Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Alicia K. Morgans, MD, MPH, has disclosed that she has received funds for research support from Bayer, Dendreon, Myovant, Sanofi, and Seattle Genetics and consulting fees from AAA, AstraZeneca, Astellas, Bayer, Blue Earth, Clovis, Dendreon, Exelixis, Janssen, Myovant, Myriad, Novartis, Pfizer, Sanofi, and Seattle Genetics.
David F. Penson, MD, MPH

Professor and Chair
Department of Urology
Vanderbilt University School of Medicine
Nashville, Tennessee

David F. Penson, MD, has no relevant conflict of interest to report.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for urologists and other healthcare professionals who care for patients with prostate cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with prostate cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 06, 2021, through October 05, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Advances in Prostate Cancer: Androgen Deprivation Therapy Across the Disease Continuum
  • CME

Loading...
In this interactive on-demand webcast, expert faculty members discuss current clinical guidance and key data on the optimal use of GnRH agonists and antagonists, androgen receptor inhibitors, and other treatments for nonmetastatic or metastatic prostate cancer.
Daniel W. Lin, MD
Alicia K. Morgans, MD, MPH
David F. Penson, MD, MPH
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: October 6, 2021 Expiration: October 5, 2022

Related Content

From Clinical Care Options (CCO), an expert video webinar on immunotherapy and targeted agents in RCC treatment

Elizabeth R. Plimack, MD, MS
Program Director
Rana R. McKay, MD Brian Rini, MD, FASCO
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 18, 2021 Expired: November 17, 2022

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

From Clinical Care Options (CCO), experts discuss advances in prostate cancer treatment, including use of GnRH antagonists and androgen receptor inhibitors.

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD, MPH Released: November 2, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Astellas
Bayer HealthCare Pharmaceuticals Inc.
Myovant Sciences Ltd.
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue